European Biotech Acquisition Stock Fundamentals
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess European Biotech's long-term financial health and intrinsic value.
European |
European Biotech Acquisition Company Number Of Shares Shorted Analysis
European Biotech's Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
More About Number Of Shares Shorted | All Equity Analysis
Shares Shorted | = | Shorted by Public | + | by Institutions |
Current European Biotech Number Of Shares Shorted | 258.83 K |
Most of European Biotech's fundamental indicators, such as Number Of Shares Shorted, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, European Biotech Acquisition is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
CompetitionBased on the recorded statements, European Biotech Acquisition has 258.83 K of outstending shares currently sold short by investors. This is 95.51% lower than that of the Financial Services sector and significantly higher than that of the Shell Companies industry. The number of shares shorted for all United States stocks is 94.5% higher than that of the company.
European Biotech Acq Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining European Biotech's current stock value. Our valuation model uses many indicators to compare European Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across European Biotech competition to find correlations between indicators driving European Biotech's intrinsic value. More Info.European Biotech Acquisition is rated # 4 in current valuation category among its peers. It also is rated # 4 in shares outstanding category among its peers creating about 0.08 of Shares Outstanding per Current Valuation. The ratio of Current Valuation to Shares Outstanding for European Biotech Acquisition is roughly 12.42 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the European Biotech's earnings, one of the primary drivers of an investment's value.European Number Of Shares Shorted Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses European Biotech's direct or indirect competition against its Number Of Shares Shorted to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of European Biotech could also be used in its relative valuation, which is a method of valuing European Biotech by comparing valuation metrics of similar companies.European Biotech is currently under evaluation in number of shares shorted category among its peers.
European Fundamentals
| Current Valuation | 164.04 M | |||
| Shares Outstanding | 13.21 M | |||
| Shares Owned By Institutions | 72.30 % | |||
| Number Of Shares Shorted | 258.83 K | |||
| Price To Earning | 66.40 X | |||
| Price To Book | 1.34 X | |||
| EBITDA | 342.89 K | |||
| Net Income | 342.89 K | |||
| Cash And Equivalents | 308.1 K | |||
| Cash Per Share | 0.02 X | |||
| Current Ratio | 1.11 X | |||
| Book Value Per Share | (0.37) X | |||
| Cash Flow From Operations | (514.79 K) | |||
| Short Ratio | 0.05 X | |||
| Earnings Per Share | 0.02 X | |||
| Market Capitalization | 183.5 M | |||
| Total Asset | 129.75 M | |||
| Net Asset | 129.75 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Other Consideration for investing in European Stock
If you are still planning to invest in European Biotech Acq check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the European Biotech's history and understand the potential risks before investing.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |